NORTH CHICAGO (dpa-AFX) - Diversified healthcare company Abbott Laboratories (ABT) Sunday reported positive one-year clinical results from Absorb II, a trial comparing the safety and effectiveness of the dissolving Absorb heart device to Abbott's XIENCE family of DES.
The trial, conducted primarily in Europe, included 501 people with coronary artery disease, the most common form of heart disease.
At one year, overall clinical outcomes for Absorb were comparable to XIENCE, and people treated with Absorb experienced a significantly lower rate of angina (chest pain), a novel finding given the impact of angina on people's quality of life and its cost burden on healthcare systems.
At one year, the patient-oriented clinical endpoint of all death, all heart attacks and all revascularization was 7.3 percent for Absorb and 9.1 percent for XIENCE.
Copyright RTT News/dpa-AFX
© 2014 AFX News
